ClinicalTrials.gg
RecruitingNCT06114953Updated Nov 2, 2023

Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

A Phase 4 interventional study of Mizoribine and Mycophenolate Mofetil in Kidney Transplant Immunosuppression, sponsored by Lee's Pharmaceutical Limited. Recruiting at 6 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-02.

Sponsored by Lee's Pharmaceutical Limited · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled Jan 2023, registered Oct 2023).
  • Started Jan 2023; still recruiting 3 years 10 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This prospective, randomized controlled study is intended to enroll 152 patients in the early stages of donor kidney transplantation at six clinical centers in China between January 2023 and January 2024. All patients meeting the inclusion criteria were randomly assigned 1:1 to either Mizoribine or Mycophenolate Mofetil for 12 months. At the baseline of follow-up (before enrollment) and each follow-up point, all clinical indicators of patients were recorded to measure the therapeutic effect.

Read the detailed description

This is a multi-center, prospective, non-inferior, randomized controlled clinical study. The sick individuals and their families participating in the trial voluntarily participate and sign the "informed consent" under the premise of fully understanding the treatment plan; The treatment plan was approved by the hospital ethics committee.

A total of 152 patients from six centers nationwide will be enrolled starting from the date when the center's ethics are officially approved. The qualified recipients of donor kidney transplantation were randomly assigned 1:1 to the control group and the experimental group. The control group was treated with glucocorticoid + MPA+ tacrolimus for 12 months, and the experimental group was treated with glucocorticoid +MZR+ tacrolimus for 12 months. All subjects were followed up on the day of renal transplantation, at 1, 2 weeks and 1, 2, 3, 6, 9 and 12 months after the operation: history collection, incidence of acute rejection, survival rate of recipients, survival rate of transplanted kidney, liver and kidney function, blood routine and urine routine; Cytomegalovirus (CMV)-DNA and BK virus (BKV)-DNA copy levels were detected in blood at 1, 3, 6, 9, and 12 months after renal transplantation to assess CMV and BKV infection. Adverse reactions were recorded during follow-up.

02

Conditions studied

  • Kidney Transplant Immunosuppression

Keywords

  • Immunosuppression
  • Kidney Transplant Rejection
  • mizoribine
03

In context

Lead sponsor

Lee's Pharmaceutical Limited is the lead sponsor of 74 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. After donor kidney transplantation;
    1. Adult recipients aged 18-75 years, regardless of gender;
    1. First-time kidney transplant recipients;
    1. Voluntarily sign written .

Exclusion criteria

Exclusion Criteria:

    1. Multiple organ transplantation;
    1. DSA positive patients had ABO incompatibility and PRA>30%;
    1. Recipients with active signs of infection;
    1. Recipients with leukocyte counts below 3,000/mm3;
    1. Pregnant women, breastfeeding women or women who do not wish to use appropriate methods during the study period;
    1. Patients with severe gastrointestinal diseases and active peptic ulcer disease;
    1. suffering from any mental illness;
    1. Patients with severe heart disease and abnormal heart function;
    1. Subjects who are known to be allergic to the test drug;
    1. Recipients judged unsuitable for inclusion by other competent physicians.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Mizoribine group

    Mizoribine, glucocorticoid, tacrolimus

    Drug: Mizoribine

  • Active comparator
    Mycophenolate group

    Mycophenolate mofetil, glucocorticoid, tacrolimus

    Drug: Mycophenolate Mofetil

Interventions

  • Mizoribine+glucocorticoid+tacrolimus after kidney transplantation

  • Mycophenolate Mofetil+glucocorticoid+tacrolimus after kidney transplantation

    Also known as: Mycophenolate Acid

06

What researchers measure

Primary outcomes

  1. Serum creatinine

    Monitoring serum creatinine.

    Time frame: Postoperative 1 week, 2 weeks, 1month, 2,3,6,9,12 months

Other outcomes

  1. White blood cell

    Detect the count of white blood cell.

    Time frame: Postoperative 1 week, 2 weeks, 1month, 2,3,6,9,12 months.

  2. Cytomegalovirus DNA copies.

    Detect Cytomegalovirus DNA copies in blood.

    Time frame: Postoperative 3,6,12 months.

  3. BK Virus DNA copies.

    Detect BK virus DNA copies in blood and urine.

    Time frame: Postoperative 3,6,12 months.

  4. Uric Acid

    Check uric acid levels.

    Time frame: Postoperative 1 week, 2 weeks, 1month, 2,3,6,9,12 months.

07

Study locations

5 of 6 sites recruiting
08

References and documents

Publications

  • Shi Y, Liu H, Chen XG, Shen ZY. Efficacy and Safety of Mizoribine Combined With Tacrolimus in Living Donor Kidney Transplant Recipients: 3-Year Results by a Chinese Single Center Study. Transplant Proc. 2019 Jun;51(5):1337-1342. doi: 10.1016/j.transproceed.2019.03.014. PubMed 31155174 ↗
  • Ju MK, Huh KH, Park KT, Kim SJ, Cho BH, Kim CD, So BJ, Kang CM, Lee S, Joo DJ, Kim YS. Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety. Transplant Proc. 2013 May;45(4):1481-6. doi: 10.1016/j.transproceed.2012.12.028. PubMed 23726602 ↗
  • Huh KH, Lee JG, Ha J, Oh CK, Ju MK, Kim CD, Cho HR, Jung CW, Lim BJ, Kim YS; RECORD Study. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial. Nephrol Dial Transplant. 2017 Aug 1;32(8):1415-1424. doi: 10.1093/ndt/gfx093. PubMed 28810721 ↗

Individual participant data

Plan to share: No — No IPD shared plan.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06114953
Responsible party
Sponsor
First posted
Nov 2, 2023
Start date
Jan 1, 2023
Primary completion
Jan 1, 2025 (estimated)
Completion
Mar 1, 2025 (estimated)
Last update
Nov 2, 2023

Study contacts

SHI JI HAN, Master
Contact
shiji.han@leespharm.com
13929517813
TAO LIN, Doctor
study chair · West China Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mizoribine

Start the discussion